Employer Health Plans Drop GLP-1 Weight-Loss Drug Coverage
Rising premiums are pushing employer-sponsored plans to cut GLP-1 obesity drug benefits, leaving workers to weigh alternative options for 2027.
A growing number of employer-sponsored health insurance plans are eliminating coverage for GLP-1 medications prescribed for weight loss, a shift driven largely by escalating premium costs that companies are increasingly unwilling to absorb.
GLP-1 drugs, which include popular obesity treatments, have seen surging demand in recent years, placing significant financial pressure on employer benefit programs. As plan administrators weigh the cost of covering these medications against broader workforce healthcare budgets, many are opting to remove the benefit entirely rather than pass higher costs to employees through elevated premiums.
Read more I Bonds Now Yield 5.51%: What Investors Should Know First →
Workers who lose employer-based GLP-1 coverage are not entirely without recourse. Alternative pathways being considered for the 2027 benefit year include pharmacy discount programs, manufacturer patient-assistance offerings, and potential individual marketplace options that may provide some access to the medications at reduced out-of-pocket expense.
The trend reflects a broader tension in employer healthcare strategy: balancing the demonstrable clinical value of obesity treatments against their considerable cost. Employers that retain GLP-1 coverage are increasingly introducing utilization management tools, such as prior authorization requirements and step-therapy protocols, to limit expenditures while preserving some level of access for employees who meet clinical criteria.
As open-enrollment seasons approach, benefits advisers are urging affected workers to review plan documents carefully and explore all available coverage alternatives before the changes take effect. Continue reading at US Top News and Analysis.
